Design and Implementation of a Nationwide Population-Based Longitudinal Survey of SARS-CoV-2 Infection in Spain: The ENE-COVID Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Public Health Association Country of Publication: United States NLM ID: 1254074 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1541-0048 (Electronic) Linking ISSN: 00900036 NLM ISO Abbreviation: Am J Public Health Subsets: MEDLINE
    • Publication Information:
      Publication: Washington, DC : American Public Health Association
      Original Publication: New York [etc.]
    • Subject Terms:
      COVID-19*; Aged, 80 and over ; Humans ; SARS-CoV-2 ; Spain/epidemiology ; Seroepidemiologic Studies ; Surveys and Questionnaires
    • Abstract:
      Data System. The Spanish National Seroepidemiological Survey of SARS-CoV-2 (or ENE-COVID; SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] is the causative agent of COVID-19) was funded by the Spanish Ministry of Health, the Instituto de Salud Carlos III, and the Spanish National Health System. Data Collection/Processing. A stratified 2-stage probability sampling was used to select a representative cohort of the noninstitutionalized population of Spain. ENE-COVID collected longitudinal data from epidemiological questionnaires and 2 SARS-CoV-2 IgG antibody tests. From April 27 to June 22, 2020, 68 287 participants (77.0% of contacted persons) received a point-of-care test and 61 095 (68.9%) also underwent a laboratory immunoassay. A second follow-up phase was conducted between November 16 and 30, 2020. Data Analysis/Dissemination. Analyses use weights to adjust for oversampling and nonresponse and account for design effects of stratification and clustering. ENE-COVID data for research purposes will be available upon request from the official study Web page. Public Health Implications. ENE-COVID, a nationwide population-based study, allowed monitoring seroprevalence of antibodies against SARS-CoV-2 at the national and regional levels, providing accurate figures by gender, age (from babies to nonagenarians), and selected risk factors; characterizing symptomatic and asymptomatic infections; and estimating the infection fatality risk during the first pandemic wave. ( Am J Public Health . 2023;113(5):525-532. https://doi.org/10.2105/AJPH.2022.307167).
    • Comments:
      Comment in: Am J Public Health. 2023 May;113(5):517-519. (PMID: 36893371)
    • References:
      J Clin Epidemiol. 2021 Nov;139:240-254. (PMID: 34126206)
      Lancet. 2020 Nov 7;396(10261):1484-1485. (PMID: 33160561)
      BMJ. 2020 Nov 27;371:m4509. (PMID: 33246972)
      Am J Public Health. 2021 Mar;111(3):414-415. (PMID: 33566650)
      Infect Ecol Epidemiol. 2020 Apr 14;10(1):1754538. (PMID: 32363011)
      Lancet. 2020 Aug 22;396(10250):535-544. (PMID: 32645347)
    • Publication Date:
      Date Created: 20230309 Date Completed: 20230407 Latest Revision: 20230915
    • Publication Date:
      20240628
    • Accession Number:
      PMC10088947
    • Accession Number:
      10.2105/AJPH.2022.307167
    • Accession Number:
      36893375